Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

API-CAT Investigators' Decisions on Anticoagulation following Extended Treatment for Cancer VTE.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same author

Predicting Age-Related Facial Hyperpigmentation via Dermatologist Knowledge Elicitation and Generative Modeling.

Dermatology and therapy·2026
Same author

Development and external validation of an international score to predict cancer 1 year after venous thromboembolism.

European journal of internal medicine·2026
Same author

Head and neck manifestations associated with hidradenitis suppurativa: A retrospective multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.

The New England journal of medicine·2026
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Psoriasis onset with tocilizumab

Anne Grasland1, Emmanuel Mahé, Edouard Raynaud

  • 1Service de médecine interne, hôpital Louis-Mourier, HUNPVS, AP-HP, 178, rue des Renouillers, 92700 Colombes, France.

Joint Bone Spine
|June 5, 2013
PubMed
Summary

No abstract available in PubMed .

Keywords:
PsoriasisRheumatoid arthritisTocilizumab

Related Experiment Videos

Last Updated: May 10, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013